Sun Pharma Advanced Research Company (SPARC) and its parent Sun Pharma have entered into a licensing pact for its Elepsia tablets, used in the treatment of epilepsy, in the US market for an upfront payment of $10 million.
As per the agreement, SPARC will license Elepsia XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market.
It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of Elepsia XR. Elepsia XR was approved by the USFDA in March 2015.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1877.25 |
| Dr. Reddys Lab | 1287.65 |
| Cipla | 1335.20 |
| Zydus Lifesciences | 946.45 |
| Lupin | 2242.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: